Does stopping a GLP-1 drug improve heart health if you regain weight?
No — the evidence shows the opposite. In a real-world study of 550 people with type 2 diabetes followed for a median of 5 years, those who stopped their GLP-1 receptor agonist had a 3.4 times higher risk of a major cardiovascular event (heart attack, stroke, or cardiovascular death) compared to those who stayed on the drug, even after accounting for changes in body weight and blood sugar [3]. The same study found that in people who already had heart disease, stopping the drug still doubled the risk (2.7 times higher) [3]. This means the cardiovascular protection is tied to active use of the medication, not to the weight loss itself.
A much larger study of over 215,000 people with diabetes mapped 175 health outcomes and found that GLP-1 use reduced the risk of cardiometabolic disorders, including heart disease and stroke, compared to usual care [4]. But that protection is a drug effect — it does not persist after discontinuation. The 2025 SELECT trial data cited in a review paper confirms that semaglutide 2.4 mg reduced major cardiovascular events by 20%, but also notes that rapid weight rebound occurs when the drug is stopped, and that obesity requires continuous long-term therapy [5].
What about weight rebound in pregnancy — does it carry any benefit?
No benefit — it actually harms. A 2026 study of nearly 900 women who used GLP-1 drugs before pregnancy found that those who stopped the drug abruptly close to conception had a 53% higher risk of developing gestational diabetes, and this was linked to a steeper weight rebound (an extra 1.3 kg/m² of BMI gain during pregnancy) [1]. In contrast, women who stopped the drug earlier (6–18 months before pregnancy) and had only a modest weight rebound (0.6 kg/m² extra gain) had the same gestational diabetes risk as women who never took the drugs [1]. This shows that the timing and speed of weight regain matter: rapid rebound erases any potential metabolic carry-over effect.
The same study matched women for pre-pregnancy BMI and still found the higher risk with abrupt discontinuation, meaning the problem is not just being heavier — it is the rapid weight gain itself that disrupts metabolic health [1].
Why doesn't weight rebound improve cardiometabolic risk on its own?
Because the cardiometabolic benefits of GLP-1 drugs come from direct effects on the heart, blood vessels, and inflammation — not just from weight loss. In the real-world study of people with type 2 diabetes, changes in BMI and blood sugar did not explain the higher heart risk after stopping the drug; the risk was driven by the drug's absence itself [3]. Similarly, the large mapping study found that GLP-1 use reduced risks for substance use disorders, neurocognitive decline, and infections — effects that go far beyond weight [4]. These benefits are pharmacodynamic (drug-driven), not a lasting metabolic reset.
The review paper on obesity as a multisystem disease emphasizes that weight rebound after stopping GLP-1 drugs is the norm, and that sustained cardioprotection requires continuous therapy [5]. In other words, the weight regain itself is a marker of lost drug effect, not a separate process that could somehow be beneficial.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 3 from 2024 or later, 5 in Q1 journals, collectively cited 312 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 46 papers retrieved from a database of over 500 million.
Sources used in this answer
Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
In a retrospective cohort of nearly 900 women, abrupt discontinuation of GLP-1 drugs close to conception was linked to a 53% higher risk of gestational diabetes, driven by rapid weight rebound, while earlier discontinuation with modest rebound showed no increased risk.
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
In a real-world study of 1,822 people with type 1 diabetes, GLP-1 receptor agonists reduced HbA1c by 0.5% but were associated with less kidney and heart protection compared to SGLT2 inhibitors, and did not examine weight rebound.
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
In a real-world study of 550 people with type 2 diabetes, stopping a GLP-1 drug was associated with a 3.4-fold higher risk of major cardiovascular events in primary prevention and a 2.7-fold higher risk in secondary prevention, independent of weight or blood sugar changes.
Mapping the effectiveness and risks of GLP-1 receptor agonists
In a large cohort of over 215,000 people with diabetes, GLP-1 use was associated with reduced risk of cardiometabolic disorders, substance use disorders, and neurocognitive decline compared to usual care, but the benefits are drug-dependent.
Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches
A 2026 review confirms that semaglutide 2.4 mg reduces major cardiovascular events by 20% (SELECT trial) but notes rapid weight rebound upon drug cessation, emphasizing that obesity requires continuous long-term therapy for sustained cardioprotection.